Information on this site is not intended as medical advice and should not be used as a substitute for consulting with a qualified doctor.
Vabysmo (faricimab) is the first bispecific antibody designed for the eye. It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilising blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking both pathways involving Ang-2 and VEGF-A, Vabysmo is designed to stabilise blood vessels.1
In Bangladesh Vabysmo is approved for the following indications.2
Vabysmo is a bispecific angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of:
Neovascular (wet) age-related macular degeneration (nAMD)
Diabetic macular edema (DME)
Macular edema secondary to retinal vein occlusion (RVO).
For more disease and medicine related queries you may discuss with your physician.
In Bangladesh Vabysmo is available as
Vials 6 mg/0.05 mL
To ensure patient safety and quality, it is strongly recommended to verify that, each medicine comes with the Roche Hologram Sticker, DGDA approved DAR (Drug Administration Registration) Number imprinted on it. Neither Radiant nor Roche Bangladesh takes liability of any other sources of products.
References:
Roche | Vabysmo (faricimab-svoa). [Internet; cited 2024, January 30]. Retrieved from https://www.roche.com/solutions/pharma/productid-0a6b3497-d8a2-4a5f-a2d4-b0ffa5769fea
Vabysmo Product Information RO-6867461 November-2023